News

Immuneering Shares Promising Data on New Pancreatic Cancer Treatment

Immuneering Shares Promising Data on New Pancreatic Cancer Treatment

Immuneering Corporation Announces New Survival Data

Exciting developments are underway at Immuneering Corporation, known for its innovative approach to oncology. This clinical-stage biotechnology firm is gearing up to disclose updated overall survival data from its Phase 2a trial involving the drug combination atebimetinib and modified Gemcitabine/nab-paclitaxel (mGnP) for patients battling pancreatic cancer. The announcement is set to take place on an investor call scheduled for September 25.

Key Details of the Upcoming Announcement

The event will highlight the performance of 34 pancreatic cancer patients who received the treatment under observation for a median of nine months. Immuneering’s commitment to advancing cancer research plays a significant role in this breakthrough, as they aim to improve patient outcomes with more effective therapies.

Investor Call Schedule

On the morning of September 25, at 8 a.m. ET, Immuneering will conduct a live webcast of the investor call. This will provide an opportunity for investors and stakeholders to hear firsthand about the promising results. The archived version will be available in the Investor Relations section of their website, ensuring that those unable to attend live can still engage with this critical information.

Scientific Presentations at Major Conferences

Following the initial announcement, Immuneering is set to present its findings at the prestigious PanCAN Scientific Summit on September 28. They will showcase the updated survival statistics through a poster presentation. This is a significant platform for sharing research findings with the wider oncology community, aiming to affect positive change in treatment protocols for pancreatic cancer.

Understanding the Challenge of Pancreatic Cancer

Pancreatic cancer remains one of the most challenging types of cancer to treat, with standard therapies yielding less than favorable outcomes. Current statistics indicate that under half of patients receiving conventional treatments, such as Gemcitabine and nab-paclitaxel, survive beyond the six-month mark. In contrast, Immuneering reported an impressive 94% overall survival (OS) rate at the six-month milestone with their treatment combination.

CEO Insights on the Treatment's Potential

Dr. Ben Zeskind, Co-founder and CEO of Immuneering Corporation, expressed enthusiasm over the recent findings. He emphasized the importance of the nine-month median follow-up as a milestone, especially given the daunting prognosis faced by patients using standard care options. Dr. Zeskind highlighted that atebimetinib was designed with durability and tolerability in mind, aspiring to provide patients with a viable alternative that ensures a better quality of life.

Future Directions for Immuneering

In addition to the survival data, Immuneering plans to expound on preclinical data involving Deep Cyclic Inhibitors at the upcoming 7th RAS-Targeted Drug Development Summit. This presents another opportunity for the company to highlight its innovative pipeline and its commitment to advancing cancer treatment methodologies.

About Immuneering Corporation

Based in Cambridge, Massachusetts, Immuneering Corporation focuses on developing a novel class of cancer medicines named Deep Cyclic Inhibitors. The lead candidate, atebimetinib (IMM-1-104), is an oral, once-daily medication aimed at enhancing both durability and tolerance against the backdrop of RAS-mutated cancers, including pancreatic tumors. Immuneering continues to pursue additional early-stage programs, reinforcing its role as a forward-thinking company in the oncology space.

Frequently Asked Questions

What is the significance of the updated survival data announced by Immuneering?

The updated survival data highlights the effectiveness of atebimetinib in treating pancreatic cancer, showing a much higher overall survival rate in comparison to traditional treatments.

How can investors participate in the upcoming call?

Investors can join the investor call by accessing the live webcast available on Immuneering's Investor Relations webpage.

What are Deep Cyclic Inhibitors?

Deep Cyclic Inhibitors are a new class of cancer drugs developed by Immuneering, designed to target and inhibit critical pathways involved in the survival and proliferation of cancer cells.

Where will Immuneering present its findings?

Immuneering will share findings at both the PanCAN Scientific Summit and the RAS-Targeted Drug Development Summit.

How is Immuneering addressing the challenges of pancreatic cancer therapy?

Immuneering focuses on innovative drug development aimed at improving survival rates and reducing side effects for patients with pancreatic cancer, seeking to provide new treatment options that could enhance patient outcomes.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 264

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 317

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 367

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 414

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 217

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 238

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 121

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Elanco Secures FDA EUA for Credelio in Fighting NWS in Dogs

Updated Category News Views 275

Elanco's Innovative Step Against New World Screwworm Elanco Animal Health Incorporated (NYSE: ELAN) has achieved a significant milestone, receiving the first Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its product, Credelio™ (lotilaner), designed to treat infestations of New World Screwworm (NWS) in dogs. This groundbreaking...

Continue Reading
Hillary Ashton Sells Teradata Shares: Insights and Implications

Updated Category News Views 412

Hillary Ashton’s Sale of Teradata Shares: A Closer Look In an important insider transaction, Hillary Ashton, who is the Chief Product Officer at Teradata (TDC), recently sold 14,962 shares of the company's stock. This sale brought in a total of $411,903, as revealed in a recent SEC filing that highlights insider activity within the company. Currently, Teradata's stock...

Continue Reading
Legal Updates for Investors of Humana Inc. Amid Lawsuit

Updated Category News Views 158

Understanding the Ongoing Lawsuit Against Humana Inc. Investors focusing on the recent activities surrounding Humana Inc. (NYSE: HUM) should be aware of a significant lawsuit that has implications for individuals who acquired shares prior to July 2022. The Shareholders Foundation, Inc. has provided updates concerning the ongoing legal proceedings relevant to these...

Continue Reading
Empowering Local Job Seekers: The Trimborns of AtWork Tampa

Updated Category News Views 231

AtWork Opens New Storefront in Tampa, Florida AtWork, a prominent staffing franchise known for empowering job seekers and fostering company growth, has expanded its presence with a new location in Tampa. This strategic establishment at 8402 Laurel Fair Circle, Suite 101, stands across the Florida State Fairgrounds, ready to cater to the needs of the local workforce. Meet...

Continue Reading
Investor Claims Wall Street is Collapsing Cryptocurrency Values

Updated Category News Views 227

Investor Claims Wall Street is Collapsing Cryptocurrency Values Mike Alfred, a noted investor and proponent of Bitcoin, has raised significant concerns regarding potential manipulation of the cryptocurrency markets by major Wall Street players. He believes that these entities are actively working to drive down Bitcoin prices specifically to pressure companies like...

Continue Reading